Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype

Losartan is metabolized by polymorphic CYP2C9 to E‐3174. Our aim was to evaluate the pharmacokinetics of losartan and E‐3174 in relation to the CYP2C9 genotype.

[1]  J. Miners,et al.  Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers , 1990, Clinical pharmacology and therapeutics.

[2]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[3]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[4]  J. Weide,et al.  The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. , 2001, Pharmacogenetics.

[5]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[6]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[7]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[8]  E. Nanba,et al.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. , 2000, Pharmacogenetics.

[9]  F. Guengerich,et al.  Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[10]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[11]  L Gillen,et al.  Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174 , 1999, Clinical pharmacology and therapeutics.

[12]  K. Williamson,et al.  The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers , 1999, Journal of clinical pharmacology.

[13]  J. Miners,et al.  Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. , 2003, British journal of clinical pharmacology.

[14]  E. Yukawa,et al.  The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.

[15]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[16]  A. Rettie,et al.  A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin , 1999, Epilepsy Research.

[17]  G. Alván,et al.  PHARMACOKINETICS AND DISPOSITION , 1999 .

[18]  M. Ingelman-Sundberg,et al.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.

[19]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[20]  J. Brockmöller,et al.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.

[21]  P. Neuvonen,et al.  Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174 , 1998, European Journal of Clinical Pharmacology.

[22]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[23]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[24]  J. Miners,et al.  Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. , 1996, Methods in enzymology.

[25]  M. Lo,et al.  An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. , 1997, Journal of pharmaceutical and biomedical analysis.

[26]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[27]  J. Miners,et al.  Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. , 1993, Pharmacogenetics.

[28]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[29]  R. Preisig,et al.  Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man , 2004, European Journal of Clinical Pharmacology.

[30]  D. Kazierad,et al.  Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers , 1997, Clinical pharmacology and therapeutics.

[31]  S. Higuchi,et al.  Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. , 2000, Therapeutic drug monitoring.

[32]  Y. Christen,et al.  Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist , 1992, Clinical pharmacology and therapeutics.

[33]  R. Miller,et al.  The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[34]  K. Furusho,et al.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.

[35]  M. Romkes,et al.  Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. , 1991, Biochemistry.

[36]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[37]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.